BioCentury
ARTICLE | Company News

Covis gains full rights to ciclesonide drugs from AZ

November 16, 2018 4:00 PM UTC

Covis Pharma S.a.r.l. (Zug, Sweden) will acquire ex-U.S. rights to Alvesco, Omnaris and Zetonna from AstraZeneca plc (LSE:AZN; NYSE:AZN) for $350 million. Covis acquired U.S. rights to the drugs, all of which contain the active ingredient ciclesonide, in 2017.

AZ, which reported combined 2017 sales for the drugs of $106 million, is eligible for up to $21 million in sales milestones...